| 1 | immediately | 7,965 |
| 2 | shortly | 742 |
| 3 | d19 | 5 |
| 4 | 0h-c | 4 |
| 5 | 10minutes | 4 |
| 6 | 24-48h | 4 |
| 7 | 15h | 3 |
| 8 | 24-36h | 3 |
| 9 | 24wk | 3 |
| 10 | 3-6h | 3 |
| 11 | 30-60min | 3 |
| 12 | 8-10weeks | 3 |
| 13 | failure/regain | 3 |
| 14 | recurring/progressing | 3 |
| 15 | spears | 3 |
| 16 | 'looking | 2 |
| 17 | 'worsening | 2 |
| 18 | 0.5±0.6 | 2 |
| 19 | 216-h | 2 |
| 20 | allodynia-free | 2 |
| 21 | cenp-m | 2 |
| 22 | circumferences/second | 2 |
| 23 | cortolones | 2 |
| 24 | hfnhrv | 2 |
| 25 | intra-articulary | 2 |
| 26 | lead-car | 2 |
| 27 | maldigesters | 2 |
| 28 | microprojections | 2 |
| 29 | naphthyridine-3-carboxamide | 2 |
| 30 | otoscopically | 2 |
| 31 | pre-or | 2 |
| 32 | preand | 2 |
| 33 | renorrhaphy | 2 |
| 34 | reulcerations | 2 |
| 35 | sphygmomanometrically | 2 |
| 36 | strephenopodia | 2 |
| 37 | vogels | 2 |
| 38 | ~30min | 2 |
| 39 | 'wake | 1 |
| 40 | -1.08°c | 1 |
| 41 | -4.2-19.0 | 1 |
| 42 | -bounce | 1 |
| 43 | -hydroxy-clarithromycin | 1 |
| 44 | -manufactured | 1 |
| 45 | -o-phosphotriesters | 1 |
| 46 | /unit | 1 |
| 47 | 0.27-0.47 | 1 |
| 48 | 0.3±0.3°c | 1 |
| 49 | 0.47±0.15 | 1 |
| 50 | 0.5-1.0s | 1 |
| 51 | 0.54±0.96 | 1 |
| 52 | 0.68±0.82 | 1 |
| 53 | 0.75±0.93 | 1 |
| 54 | 0.9±0.7881 | 1 |
| 55 | 02+/-0.68 | 1 |
| 56 | 08:00-10:00 | 1 |
| 57 | 1-1½h | 1 |
| 58 | 1-40day | 1 |
| 59 | 1-5years | 1 |
| 60 | 1-log-reduction | 1 |
| 61 | 1.4s | 1 |
| 62 | 1.8-3.6°c | 1 |
| 63 | 10-11weeks | 1 |
| 64 | 10.8±1.86 | 1 |
| 65 | 116.27 | 1 |
| 66 | 12-48h | 1 |
| 67 | 125min | 1 |
| 68 | 13.4±1.98 | 1 |
| 69 | 135-day | 1 |
| 70 | 135/86 | 1 |
| 71 | 14,265 | 1 |
| 72 | 15-24h | 1 |
| 73 | 15-50-fold | 1 |
| 74 | 160±35 | 1 |
| 75 | 165±33 | 1 |
| 76 | 17±22 | 1 |
| 77 | 18-24-month | 1 |
| 78 | 180minutes | 1 |
| 79 | 18completed | 1 |
| 80 | 18±10 | 1 |
| 81 | 2-3weeks | 1 |
| 82 | 2-4hours | 1 |
| 83 | 2.49±1.3 | 1 |
| 84 | 2.77+/-1.35 | 1 |
| 85 | 2.88+/-2.31 | 1 |
| 86 | 20hr | 1 |
| 87 | 22.27:28.28 | 1 |
| 88 | 23.6° | 1 |
| 89 | 24.29° | 1 |
| 90 | 25-oh-vd | 1 |
| 91 | 25.6±27.9months | 1 |
| 92 | 256+/-125 | 1 |
| 93 | 25days | 1 |
| 94 | 300ms | 1 |
| 95 | 30mins | 1 |
| 96 | 32-months | 1 |
| 97 | 35±15days | 1 |
| 98 | 36hrs | 1 |
| 99 | 36month | 1 |
| 100 | 4-24h | 1 |
| 101 | 4-6h | 1 |
| 102 | 4.2±2.4 | 1 |
| 103 | 4.75±0.60 | 1 |
| 104 | 4.7±1.4 | 1 |
| 105 | 403±152m | 1 |
| 106 | 40d | 1 |
| 107 | 4wk-intervals | 1 |
| 108 | 5.16+/-0.50mmolh/l | 1 |
| 109 | 5.76+/-0.96 | 1 |
| 110 | 5.837±3.217μg/ml | 1 |
| 111 | 51- | 1 |
| 112 | 56d | 1 |
| 113 | 5hours | 1 |
| 114 | 5·12-1·82 | 1 |
| 115 | 6,444 | 1 |
| 116 | 6.09+/-0.71mmolh/l | 1 |
| 117 | 6.9:1 | 1 |
| 118 | 6hrs | 1 |
| 119 | 6~months | 1 |
| 120 | 7-11h | 1 |
| 121 | 7.69±2.1 | 1 |
| 122 | 7.8±1.2 | 1 |
| 123 | 70minutes | 1 |
| 124 | 789.1±2.7pg/ml | 1 |
| 125 | 7mg | 1 |
| 126 | 8-12s | 1 |
| 127 | 8-question | 1 |
| 128 | 9.1±1.6 | 1 |
| 129 | 9.5±2.2 | 1 |
| 130 | 9.87±2.01 | 1 |
| 131 | 91.36 | 1 |
| 132 | 9394 | 1 |
| 133 | 97.6-108.2 | 1 |
| 134 | =550 | 1 |
| 135 | accessit | 1 |
| 136 | ached | 1 |
| 137 | alsfrs-r. | 1 |
| 138 | angina/ischaemia | 1 |
| 139 | anually | 1 |
| 140 | arms.outcomes | 1 |
| 141 | asthemia | 1 |
| 142 | autoradiographically | 1 |
| 143 | azothioprine | 1 |
| 144 | aα/-low-thresholdmechanoreceptors | 1 |
| 145 | bupivacaine.the | 1 |
| 146 | cather | 1 |
| 147 | ca₂p₂o₇ | 1 |
| 148 | chemiotherapy | 1 |
| 149 | cisplatin-chemotherapy | 1 |
| 150 | clariti | 1 |
| 151 | compacter | 1 |
| 152 | componed | 1 |
| 153 | creatinine-creatinine | 1 |
| 154 | cyclohexadienone | 1 |
| 155 | dasatinib/nilotinib | 1 |
| 156 | day-9 | 1 |
| 157 | day/28°c | 1 |
| 158 | dermotomy | 1 |
| 159 | domain-related | 1 |
| 160 | during/or | 1 |
| 161 | embryolethality | 1 |
| 162 | ent-infections | 1 |
| 163 | enthesopathies | 1 |
| 164 | equipotence | 1 |
| 165 | evaluation.the | 1 |
| 166 | extra-abdominally | 1 |
| 167 | graft-failure | 1 |
| 168 | hypersalivated | 1 |
| 169 | hypogamma-globulinemia | 1 |
| 170 | hypogonadotrophism | 1 |
| 171 | immediatly | 1 |
| 172 | improvementrates | 1 |
| 173 | increased/induced | 1 |
| 174 | indiscriminantly | 1 |
| 175 | inferlity | 1 |
| 176 | inmediately | 1 |
| 177 | ishlt≥cav1 | 1 |
| 178 | ism-r. | 1 |
| 179 | joseonpildam | 1 |
| 180 | l/min/mu | 1 |
| 181 | ldl-cholesterol-levels | 1 |
| 182 | lnms | 1 |
| 183 | luated | 1 |
| 184 | milichia | 1 |
| 185 | ml±94.1 | 1 |
| 186 | mrsa/hse | 1 |
| 187 | mumol/l/week | 1 |
| 188 | n=1907 | 1 |
| 189 | nitiws | 1 |
| 190 | nonconsecutively | 1 |
| 191 | not-progressing | 1 |
| 192 | ntad | 1 |
| 193 | odd-score | 1 |
| 194 | off-dose | 1 |
| 195 | ofhemostasis | 1 |
| 196 | one/two | 1 |
| 197 | oxide-isoflurane | 1 |
| 198 | petequiae | 1 |
| 199 | phenotypology | 1 |
| 200 | ph≥7.25 | 1 |
| 201 | plateauxed | 1 |
| 202 | prandially | 1 |
| 203 | preand- | 1 |
| 204 | prevention-suggested | 1 |
| 205 | profilometery | 1 |
| 206 | psr4 | 1 |
| 207 | ptc-monitoring | 1 |
| 208 | quasi-stable | 1 |
| 209 | re-catherization | 1 |
| 210 | re-contextualization | 1 |
| 211 | re-graded | 1 |
| 212 | re-grown | 1 |
| 213 | re-increased | 1 |
| 214 | reanaysis | 1 |
| 215 | recircumcision | 1 |
| 216 | reprimed | 1 |
| 217 | restenosing | 1 |
| 218 | rv0386 | 1 |
| 219 | self-bolus | 1 |
| 220 | serum-bdnf | 1 |
| 221 | spectrophotometerically | 1 |
| 222 | supercompensation | 1 |
| 223 | svr48 | 1 |
| 224 | sysytem | 1 |
| 225 | training/therapy | 1 |
| 226 | twenty-one-day | 1 |
| 227 | uroflow-metrie | 1 |
| 228 | vs.t=0 | 1 |
| 229 | weight-regain | 1 |
| 230 | σlnaa | 1 |
| 231 | €696 | 1 |
| 232 | ∆leptin | 1 |
| 233 | ≥1:330 | 1 |
| 234 | ≥6.0mg/dl | 1 |
| 235 | ≥6·7 | 1 |
| 1 | 'looking | 2 |
| 2 | 'wake | 1 |
| 3 | 'worsening | 2 |
| 4 | -1.08°c | 1 |
| 5 | -4.2-19.0 | 1 |
| 6 | -bounce | 1 |
| 7 | -hydroxy-clarithromycin | 1 |
| 8 | -manufactured | 1 |
| 9 | -o-phosphotriesters | 1 |
| 10 | /unit | 1 |
| 11 | 0.27-0.47 | 1 |
| 12 | 0.3±0.3°c | 1 |
| 13 | 0.47±0.15 | 1 |
| 14 | 0.5-1.0s | 1 |
| 15 | 0.54±0.96 | 1 |
| 16 | 0.5±0.6 | 2 |
| 17 | 0.68±0.82 | 1 |
| 18 | 0.75±0.93 | 1 |
| 19 | 0.9±0.7881 | 1 |
| 20 | 02+/-0.68 | 1 |
| 21 | 08:00-10:00 | 1 |
| 22 | 0h-c | 4 |
| 23 | 1-1½h | 1 |
| 24 | 1-40day | 1 |
| 25 | 1-5years | 1 |
| 26 | 1-log-reduction | 1 |
| 27 | 1.4s | 1 |
| 28 | 1.8-3.6°c | 1 |
| 29 | 10-11weeks | 1 |
| 30 | 10.8±1.86 | 1 |
| 31 | 10minutes | 4 |
| 32 | 116.27 | 1 |
| 33 | 12-48h | 1 |
| 34 | 125min | 1 |
| 35 | 13.4±1.98 | 1 |
| 36 | 135-day | 1 |
| 37 | 135/86 | 1 |
| 38 | 14,265 | 1 |
| 39 | 15-24h | 1 |
| 40 | 15-50-fold | 1 |
| 41 | 15h | 3 |
| 42 | 160±35 | 1 |
| 43 | 165±33 | 1 |
| 44 | 17±22 | 1 |
| 45 | 18-24-month | 1 |
| 46 | 180minutes | 1 |
| 47 | 18completed | 1 |
| 48 | 18±10 | 1 |
| 49 | 2-3weeks | 1 |
| 50 | 2-4hours | 1 |
| 51 | 2.49±1.3 | 1 |
| 52 | 2.77+/-1.35 | 1 |
| 53 | 2.88+/-2.31 | 1 |
| 54 | 20hr | 1 |
| 55 | 216-h | 2 |
| 56 | 22.27:28.28 | 1 |
| 57 | 23.6° | 1 |
| 58 | 24-36h | 3 |
| 59 | 24-48h | 4 |
| 60 | 24.29° | 1 |
| 61 | 24wk | 3 |
| 62 | 25-oh-vd | 1 |
| 63 | 25.6±27.9months | 1 |
| 64 | 256+/-125 | 1 |
| 65 | 25days | 1 |
| 66 | 3-6h | 3 |
| 67 | 30-60min | 3 |
| 68 | 300ms | 1 |
| 69 | 30mins | 1 |
| 70 | 32-months | 1 |
| 71 | 35±15days | 1 |
| 72 | 36hrs | 1 |
| 73 | 36month | 1 |
| 74 | 4-24h | 1 |
| 75 | 4-6h | 1 |
| 76 | 4.2±2.4 | 1 |
| 77 | 4.75±0.60 | 1 |
| 78 | 4.7±1.4 | 1 |
| 79 | 403±152m | 1 |
| 80 | 40d | 1 |
| 81 | 4wk-intervals | 1 |
| 82 | 5.16+/-0.50mmolh/l | 1 |
| 83 | 5.76+/-0.96 | 1 |
| 84 | 5.837±3.217μg/ml | 1 |
| 85 | 51- | 1 |
| 86 | 56d | 1 |
| 87 | 5hours | 1 |
| 88 | 5·12-1·82 | 1 |
| 89 | 6,444 | 1 |
| 90 | 6.09+/-0.71mmolh/l | 1 |
| 91 | 6.9:1 | 1 |
| 92 | 6hrs | 1 |
| 93 | 6~months | 1 |
| 94 | 7-11h | 1 |
| 95 | 7.69±2.1 | 1 |
| 96 | 7.8±1.2 | 1 |
| 97 | 70minutes | 1 |
| 98 | 789.1±2.7pg/ml | 1 |
| 99 | 7mg | 1 |
| 100 | 8-10weeks | 3 |
| 101 | 8-12s | 1 |
| 102 | 8-question | 1 |
| 103 | 9.1±1.6 | 1 |
| 104 | 9.5±2.2 | 1 |
| 105 | 9.87±2.01 | 1 |
| 106 | 91.36 | 1 |
| 107 | 9394 | 1 |
| 108 | 97.6-108.2 | 1 |
| 109 | =550 | 1 |
| 110 | accessit | 1 |
| 111 | ached | 1 |
| 112 | allodynia-free | 2 |
| 113 | alsfrs-r. | 1 |
| 114 | angina/ischaemia | 1 |
| 115 | anually | 1 |
| 116 | arms.outcomes | 1 |
| 117 | asthemia | 1 |
| 118 | autoradiographically | 1 |
| 119 | azothioprine | 1 |
| 120 | aα/-low-thresholdmechanoreceptors | 1 |
| 121 | bupivacaine.the | 1 |
| 122 | cather | 1 |
| 123 | ca₂p₂o₇ | 1 |
| 124 | cenp-m | 2 |
| 125 | chemiotherapy | 1 |
| 126 | circumferences/second | 2 |
| 127 | cisplatin-chemotherapy | 1 |
| 128 | clariti | 1 |
| 129 | compacter | 1 |
| 130 | componed | 1 |
| 131 | cortolones | 2 |
| 132 | creatinine-creatinine | 1 |
| 133 | cyclohexadienone | 1 |
| 134 | d19 | 5 |
| 135 | dasatinib/nilotinib | 1 |
| 136 | day-9 | 1 |
| 137 | day/28°c | 1 |
| 138 | dermotomy | 1 |
| 139 | domain-related | 1 |
| 140 | during/or | 1 |
| 141 | embryolethality | 1 |
| 142 | ent-infections | 1 |
| 143 | enthesopathies | 1 |
| 144 | equipotence | 1 |
| 145 | evaluation.the | 1 |
| 146 | extra-abdominally | 1 |
| 147 | failure/regain | 3 |
| 148 | graft-failure | 1 |
| 149 | hfnhrv | 2 |
| 150 | hypersalivated | 1 |
| 151 | hypogamma-globulinemia | 1 |
| 152 | hypogonadotrophism | 1 |
| 153 | immediately | 7,965 |
| 154 | immediatly | 1 |
| 155 | improvementrates | 1 |
| 156 | increased/induced | 1 |
| 157 | indiscriminantly | 1 |
| 158 | inferlity | 1 |
| 159 | inmediately | 1 |
| 160 | intra-articulary | 2 |
| 161 | ishlt≥cav1 | 1 |
| 162 | ism-r. | 1 |
| 163 | joseonpildam | 1 |
| 164 | l/min/mu | 1 |
| 165 | ldl-cholesterol-levels | 1 |
| 166 | lead-car | 2 |
| 167 | lnms | 1 |
| 168 | luated | 1 |
| 169 | maldigesters | 2 |
| 170 | microprojections | 2 |
| 171 | milichia | 1 |
| 172 | ml±94.1 | 1 |
| 173 | mrsa/hse | 1 |
| 174 | mumol/l/week | 1 |
| 175 | n=1907 | 1 |
| 176 | naphthyridine-3-carboxamide | 2 |
| 177 | nitiws | 1 |
| 178 | nonconsecutively | 1 |
| 179 | not-progressing | 1 |
| 180 | ntad | 1 |
| 181 | odd-score | 1 |
| 182 | off-dose | 1 |
| 183 | ofhemostasis | 1 |
| 184 | one/two | 1 |
| 185 | otoscopically | 2 |
| 186 | oxide-isoflurane | 1 |
| 187 | petequiae | 1 |
| 188 | phenotypology | 1 |
| 189 | ph≥7.25 | 1 |
| 190 | plateauxed | 1 |
| 191 | prandially | 1 |
| 192 | pre-or | 2 |
| 193 | preand | 2 |
| 194 | preand- | 1 |
| 195 | prevention-suggested | 1 |
| 196 | profilometery | 1 |
| 197 | psr4 | 1 |
| 198 | ptc-monitoring | 1 |
| 199 | quasi-stable | 1 |
| 200 | re-catherization | 1 |
| 201 | re-contextualization | 1 |
| 202 | re-graded | 1 |
| 203 | re-grown | 1 |
| 204 | re-increased | 1 |
| 205 | reanaysis | 1 |
| 206 | recircumcision | 1 |
| 207 | recurring/progressing | 3 |
| 208 | renorrhaphy | 2 |
| 209 | reprimed | 1 |
| 210 | restenosing | 1 |
| 211 | reulcerations | 2 |
| 212 | rv0386 | 1 |
| 213 | self-bolus | 1 |
| 214 | serum-bdnf | 1 |
| 215 | shortly | 742 |
| 216 | spears | 3 |
| 217 | spectrophotometerically | 1 |
| 218 | sphygmomanometrically | 2 |
| 219 | strephenopodia | 2 |
| 220 | supercompensation | 1 |
| 221 | svr48 | 1 |
| 222 | sysytem | 1 |
| 223 | training/therapy | 1 |
| 224 | twenty-one-day | 1 |
| 225 | uroflow-metrie | 1 |
| 226 | vogels | 2 |
| 227 | vs.t=0 | 1 |
| 228 | weight-regain | 1 |
| 229 | ~30min | 2 |
| 230 | σlnaa | 1 |
| 231 | €696 | 1 |
| 232 | ∆leptin | 1 |
| 233 | ≥1:330 | 1 |
| 234 | ≥6.0mg/dl | 1 |
| 235 | ≥6·7 | 1 |
| 1 | 51- | 1 |
| 2 | preand- | 1 |
| 3 | ism-r. | 1 |
| 4 | alsfrs-r. | 1 |
| 5 | -4.2-19.0 | 1 |
| 6 | 08:00-10:00 | 1 |
| 7 | 18±10 | 1 |
| 8 | ≥1:330 | 1 |
| 9 | =550 | 1 |
| 10 | 4.75±0.60 | 1 |
| 11 | vs.t=0 | 1 |
| 12 | 7.69±2.1 | 1 |
| 13 | ml±94.1 | 1 |
| 14 | 9.87±2.01 | 1 |
| 15 | 2.88+/-2.31 | 1 |
| 16 | 0.9±0.7881 | 1 |
| 17 | 6.9:1 | 1 |
| 18 | ishlt≥cav1 | 1 |
| 19 | 7.8±1.2 | 1 |
| 20 | 9.5±2.2 | 1 |
| 21 | 97.6-108.2 | 1 |
| 22 | 17±22 | 1 |
| 23 | 0.68±0.82 | 1 |
| 24 | 5·12-1·82 | 1 |
| 25 | 2.49±1.3 | 1 |
| 26 | 165±33 | 1 |
| 27 | 0.75±0.93 | 1 |
| 28 | 4.7±1.4 | 1 |
| 29 | 4.2±2.4 | 1 |
| 30 | 6,444 | 1 |
| 31 | 9394 | 1 |
| 32 | psr4 | 1 |
| 33 | 0.47±0.15 | 1 |
| 34 | ph≥7.25 | 1 |
| 35 | 256+/-125 | 1 |
| 36 | 2.77+/-1.35 | 1 |
| 37 | 160±35 | 1 |
| 38 | 14,265 | 1 |
| 39 | 0.5±0.6 | 2 |
| 40 | 9.1±1.6 | 1 |
| 41 | 91.36 | 1 |
| 42 | 10.8±1.86 | 1 |
| 43 | 135/86 | 1 |
| 44 | rv0386 | 1 |
| 45 | 5.76+/-0.96 | 1 |
| 46 | 0.54±0.96 | 1 |
| 47 | €696 | 1 |
| 48 | n=1907 | 1 |
| 49 | 116.27 | 1 |
| 50 | 0.27-0.47 | 1 |
| 51 | ≥6·7 | 1 |
| 52 | 22.27:28.28 | 1 |
| 53 | svr48 | 1 |
| 54 | 02+/-0.68 | 1 |
| 55 | 13.4±1.98 | 1 |
| 56 | day-9 | 1 |
| 57 | d19 | 5 |
| 58 | σlnaa | 1 |
| 59 | strephenopodia | 2 |
| 60 | milichia | 1 |
| 61 | angina/ischaemia | 1 |
| 62 | asthemia | 1 |
| 63 | hypogamma-globulinemia | 1 |
| 64 | dasatinib/nilotinib | 1 |
| 65 | 0h-c | 4 |
| 66 | 0.3±0.3°c | 1 |
| 67 | 1.8-3.6°c | 1 |
| 68 | -1.08°c | 1 |
| 69 | day/28°c | 1 |
| 70 | 40d | 1 |
| 71 | 56d | 1 |
| 72 | ntad | 1 |
| 73 | increased/induced | 1 |
| 74 | re-graded | 1 |
| 75 | ached | 1 |
| 76 | reprimed | 1 |
| 77 | componed | 1 |
| 78 | -manufactured | 1 |
| 79 | re-increased | 1 |
| 80 | domain-related | 1 |
| 81 | luated | 1 |
| 82 | hypersalivated | 1 |
| 83 | 18completed | 1 |
| 84 | prevention-suggested | 1 |
| 85 | plateauxed | 1 |
| 86 | 15-50-fold | 1 |
| 87 | preand | 2 |
| 88 | circumferences/second | 2 |
| 89 | 25-oh-vd | 1 |
| 90 | petequiae | 1 |
| 91 | equipotence | 1 |
| 92 | -bounce | 1 |
| 93 | naphthyridine-3-carboxamide | 2 |
| 94 | allodynia-free | 2 |
| 95 | bupivacaine.the | 1 |
| 96 | evaluation.the | 1 |
| 97 | uroflow-metrie | 1 |
| 98 | 'wake | 1 |
| 99 | quasi-stable | 1 |
| 100 | oxide-isoflurane | 1 |
| 101 | creatinine-creatinine | 1 |
| 102 | azothioprine | 1 |
| 103 | cyclohexadienone | 1 |
| 104 | odd-score | 1 |
| 105 | graft-failure | 1 |
| 106 | mrsa/hse | 1 |
| 107 | off-dose | 1 |
| 108 | serum-bdnf | 1 |
| 109 | 7mg | 1 |
| 110 | 'looking | 2 |
| 111 | 'worsening | 2 |
| 112 | ptc-monitoring | 1 |
| 113 | restenosing | 1 |
| 114 | not-progressing | 1 |
| 115 | recurring/progressing | 3 |
| 116 | 216-h | 2 |
| 117 | 7-11h | 1 |
| 118 | 4-24h | 1 |
| 119 | 15-24h | 1 |
| 120 | 15h | 3 |
| 121 | 3-6h | 3 |
| 122 | 4-6h | 1 |
| 123 | 24-36h | 3 |
| 124 | 12-48h | 1 |
| 125 | 24-48h | 4 |
| 126 | 18-24-month | 1 |
| 127 | 36month | 1 |
| 128 | 1-1½h | 1 |
| 129 | clariti | 1 |
| 130 | mumol/l/week | 1 |
| 131 | 24wk | 3 |
| 132 | 5.16+/-0.50mmolh/l | 1 |
| 133 | 6.09+/-0.71mmolh/l | 1 |
| 134 | ≥6.0mg/dl | 1 |
| 135 | 789.1±2.7pg/ml | 1 |
| 136 | 5.837±3.217μg/ml | 1 |
| 137 | cenp-m | 2 |
| 138 | 403±152m | 1 |
| 139 | joseonpildam | 1 |
| 140 | sysytem | 1 |
| 141 | hypogonadotrophism | 1 |
| 142 | weight-regain | 1 |
| 143 | failure/regain | 3 |
| 144 | -hydroxy-clarithromycin | 1 |
| 145 | ~30min | 2 |
| 146 | 30-60min | 3 |
| 147 | 125min | 1 |
| 148 | ∆leptin | 1 |
| 149 | recircumcision | 1 |
| 150 | supercompensation | 1 |
| 151 | re-contextualization | 1 |
| 152 | re-catherization | 1 |
| 153 | 1-log-reduction | 1 |
| 154 | 8-question | 1 |
| 155 | re-grown | 1 |
| 156 | one/two | 1 |
| 157 | lead-car | 2 |
| 158 | cather | 1 |
| 159 | compacter | 1 |
| 160 | 20hr | 1 |
| 161 | pre-or | 2 |
| 162 | during/or | 1 |
| 163 | 0.5-1.0s | 1 |
| 164 | 8-12s | 1 |
| 165 | 1.4s | 1 |
| 166 | enthesopathies | 1 |
| 167 | arms.outcomes | 1 |
| 168 | cortolones | 2 |
| 169 | improvementrates | 1 |
| 170 | 10minutes | 4 |
| 171 | 70minutes | 1 |
| 172 | 180minutes | 1 |
| 173 | 32-months | 1 |
| 174 | 25.6±27.9months | 1 |
| 175 | 6~months | 1 |
| 176 | ofhemostasis | 1 |
| 177 | reanaysis | 1 |
| 178 | 8-10weeks | 3 |
| 179 | 10-11weeks | 1 |
| 180 | 2-3weeks | 1 |
| 181 | 4wk-intervals | 1 |
| 182 | vogels | 2 |
| 183 | ldl-cholesterol-levels | 1 |
| 184 | 300ms | 1 |
| 185 | lnms | 1 |
| 186 | 30mins | 1 |
| 187 | reulcerations | 2 |
| 188 | ent-infections | 1 |
| 189 | microprojections | 2 |
| 190 | spears | 3 |
| 191 | 1-5years | 1 |
| 192 | maldigesters | 2 |
| 193 | -o-phosphotriesters | 1 |
| 194 | 6hrs | 1 |
| 195 | 36hrs | 1 |
| 196 | aα/-low-thresholdmechanoreceptors | 1 |
| 197 | 2-4hours | 1 |
| 198 | 5hours | 1 |
| 199 | self-bolus | 1 |
| 200 | nitiws | 1 |
| 201 | 35±15days | 1 |
| 202 | 25days | 1 |
| 203 | /unit | 1 |
| 204 | accessit | 1 |
| 205 | l/min/mu | 1 |
| 206 | hfnhrv | 2 |
| 207 | 135-day | 1 |
| 208 | twenty-one-day | 1 |
| 209 | 1-40day | 1 |
| 210 | phenotypology | 1 |
| 211 | renorrhaphy | 2 |
| 212 | immediately | 7,965 |
| 213 | inmediately | 1 |
| 214 | nonconsecutively | 1 |
| 215 | autoradiographically | 1 |
| 216 | otoscopically | 2 |
| 217 | spectrophotometerically | 1 |
| 218 | sphygmomanometrically | 2 |
| 219 | prandially | 1 |
| 220 | extra-abdominally | 1 |
| 221 | anually | 1 |
| 222 | immediatly | 1 |
| 223 | indiscriminantly | 1 |
| 224 | shortly | 742 |
| 225 | dermotomy | 1 |
| 226 | training/therapy | 1 |
| 227 | chemiotherapy | 1 |
| 228 | cisplatin-chemotherapy | 1 |
| 229 | intra-articulary | 2 |
| 230 | profilometery | 1 |
| 231 | embryolethality | 1 |
| 232 | inferlity | 1 |
| 233 | ca₂p₂o₇ | 1 |
| 234 | 23.6° | 1 |
| 235 | 24.29° | 1 |